Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus rhamnosus

What does the research say about Lactobacillus rhamnosus?

12 health outcomes synthesised

Lactobacillus rhamnosus has been studied across 12 health outcomes, with the strongest evidence for reducing inflammation based on 13 studies. The research populations include children with asthma and patients with chronic kidney disease, though no consistent effective dose has been identified. Most evidence is preliminary, with many studies conducted in animal models or small human trials.

Strongest evidence The highest-quality research on Lactobacillus rhamnosus, graded as low evidence strength, supports benefits for reducing inflammation (13 studies, moderate effect), improving immune function (4 studies, mixed small-to-moderate effects), and improving gastrointestinal health (3 reviews, moderate effect). For inflammation, the key human data come from a systematic review in children with asthma and an RCT in chronic kidney disease patients. No effective doses were reported in these syntheses.

Mixed or weaker evidence Several outcomes have very low evidence strength, meaning the findings are preliminary and often derived from non-human models. These include reduced oxidative stress (5 studies, animal/in vitro), improved skin barrier function (4 reviews), improved intestinal barrier function (4 animal/in vitro studies), improved gut health (3 reviews on animals/aquaculture), improved skin health (3 reviews), and improved glycemia (3 animal studies). All reported beneficial directions, but statistical significance was rarely achieved, and human data are absent for most.

Effective dose patterns Across all 12 syntheses, no consistent effective dose or formulation emerged. Most studies did not report specific doses, durations, or forms (e.g., strain, colony-forming units). This makes it impossible to identify a typical or optimal dose from the current evidence base.

Population insights Human populations studied are limited and specific: children with asthma, adults with non-dialysis chronic kidney disease, individuals with autism spectrum disorder, and patients undergoing oncological treatment. No cross-cutting pattern (e.g., age or deficiency status) was evident across outcomes. Most research remains in animal models (rodents, chickens, aquaculture species), limiting generalizability.

Notable caveats

  • Publication bias is a recurring concern—null-result studies are less likely to be published, which may overstate benefits.
  • The evidence base for every outcome is small (3–13 studies) and often consists of reviews rather than original human trials.
  • Many primary studies did not reach statistical significance, suggesting true effects may be smaller than reported.
  • For several outcomes (e.g., reduced oxidative stress, improved skin barrier), effects were observed using exopolysaccharides derived from L. rhamnosus rather than the whole probiotic, which may not reflect typical supplementation.

Frequently asked

  • What is Lactobacillus rhamnosus good for according to research?
    Research has investigated L. rhamnosus for 12 health outcomes, with the strongest evidence for reducing inflammation (13 studies, low evidence strength). Other potential benefits with limited evidence include improving immune function, gastrointestinal health, and antioxidant activity. Most findings are preliminary and based on small studies or animal models.
  • What dose of Lactobacillus rhamnosus is typically used in studies?
    No consistent effective dose has been reported across the research syntheses. Many studies did not provide specific dose, duration, or formulation details, making it impossible to identify a typical dose from the current evidence.
  • Who benefits most from Lactobacillus rhamnosus?
    The limited human research has focused on specific groups: children with asthma, adults with chronic kidney disease (non-dialysis stage 3–5), individuals with autism spectrum disorder, and patients undergoing oncological treatment. However, the evidence for these populations is sparse, and no general population data show clear benefit.
  • Are there caveats or limitations in the research on Lactobacillus rhamnosus?
    Yes, significant caveats include potential publication bias (null results less likely published), small evidence bases (3–13 studies per outcome), and reliance on reviews, animal models, or in vitro studies rather than large human trials. Many individual studies did not reach statistical significance, suggesting actual effects may be smaller.
  • Does Lactobacillus rhamnosus help with inflammation?
    All 13 studies on inflammation reported beneficial effects, with a predominantly moderate effect size. The highest-quality evidence comes from a systematic review in children with asthma and an RCT in chronic kidney disease patients. However, the overall evidence strength is low due to publication bias and many preclinical studies.
  • Does Lactobacillus rhamnosus help with skin health?
    Very low evidence from 3 review articles suggests small beneficial effects on skin health outcomes such as acne, rosacea, and wound healing. No original human clinical trials were identified, and the reviews reference both topical and oral applications. The findings are too preliminary to draw conclusions.

Most-studied combinations with Lactobacillus rhamnosus

most supplement research is combination research
Also studied with:Lactobacillus gasseri (2), Lactobacillus acidophilus (2), Bifidobacterium plantarum (3), Lactobacillus plantarum (2), bifidobacterium longum (2)
Back to top